BMY · Bristol Myers Squibb
AI read · Neutral
The AI's read
That leaves the same outside view, not new information about Bristol Myers Squibb's medicines, sales, or profits. The report gives no company update that would change its outlook.
Goldman Sachs says to keep holding Bristol Myers Squibb shares, aiming for a price of $63 each.
Neutral
Goldman Sachs kept its Hold rating and $63 target unchanged. The report adds no new company results or drug news, so it does not change Bristol Myers Squibb's outlook.
Get alerts for BMY
Follow Bristol Myers Squibb (BMY) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for BMYFree on the App Store and Google Play, or on the web.